LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: A longitudinal examination of the association between fear of COVID-19, resilience, and mental health during COVID-19 outbreak.

    Belen, Hacer

    Psychology, health & medicine

    2022  Volume 28, Issue 1, Page(s) 253–259

    Abstract: The purpose of this study was to examine the impact of fear of COVID-19 on depression and anxiety in longitudinal data and whether this relationship can be mediated by resilience. The sample of the study comprised of 144 university students (77% female ... ...

    Abstract The purpose of this study was to examine the impact of fear of COVID-19 on depression and anxiety in longitudinal data and whether this relationship can be mediated by resilience. The sample of the study comprised of 144 university students (77% female and 23% male) between 18 and 39 years of age (M = 22.74 ± 2.93) and participants completed the Fear of COVID-19 Scale (FCV-19S), Brief Resilience Scale (BRS), and Symptom Checklist-90-Revised (SCL-90-R) at Time 1 and Time 2. Mediation analyses demonstrated that resilience (T2) was a significant mediator between fear of COVID-19 (T1) and depression and anxiety (T2). The findings of the study highlight the potential key role of resilience as a protective factor against the negative effects of pandemic challenges on individuals' mental health.
    MeSH term(s) Female ; Male ; Humans ; Mental Health ; COVID-19/epidemiology ; Fear ; Anxiety/epidemiology ; Disease Outbreaks
    Language English
    Publishing date 2022-05-04
    Publishing country England
    Document type Journal Article
    ZDB-ID 1477841-5
    ISSN 1465-3966 ; 1354-8506
    ISSN (online) 1465-3966
    ISSN 1354-8506
    DOI 10.1080/13548506.2022.2073378
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Fear of COVID-19 and Mental Health: The Role of Mindfulness in During Times of Crisis.

    Belen, Hacer

    International journal of mental health and addiction

    2021  Volume 20, Issue 1, Page(s) 607–618

    Abstract: The novel coronavirus disease (COVID-19) has had a significant impact on all aspects of individuals' lives, particularly their mental health due to the fear associated with the pandemic. Thus, the current study explored the relationship between the fear ... ...

    Abstract The novel coronavirus disease (COVID-19) has had a significant impact on all aspects of individuals' lives, particularly their mental health due to the fear associated with the pandemic. Thus, the current study explored the relationship between the fear of COVID-19 and aspects of mental health, namely anxiety and depression, and will consider whether this relationship can be mediated by mindfulness. Data were collected from a student sample of 355 participants (71.5% female and 28.5% male) ranging between 18 and 41 years of age (M = 22.41 ± 3.27), with participants completing a fear of COVID-19 scale (FCV-19S), Mindfulness Attention and Awareness Scale (MAAS), and the anxiety and depression subscale of the Symptom Checklist-90-Revised (SCL-90-R). In terms of the results, correlational analyses indicated that fear of COVID-19 is inversely associated with mindfulness, while positive correlations were found with anxiety and depression. Structural equation modeling analyses demonstrated that mindfulness mediated the relationship between fear of COVID-19 and depression and anxiety. Associated implications are further discussed.
    Language English
    Publishing date 2021-04-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2235886-9
    ISSN 1557-1882 ; 1557-1874
    ISSN (online) 1557-1882
    ISSN 1557-1874
    DOI 10.1007/s11469-020-00470-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.

    Özdemir, Özlem / Zengel, Baha / Yildiz, Yaşar / Uluç, Basak Oyan / Cabuk, Devrim / Ozden, Ercan / Salim, Derya Kivrak / Paydas, Semra / Demir, Atakan / Diker, Omer / Pilanci, Kezban Nur / Sönmez, Özlem Uysal / Vatansever, Sezai / Dogan, Izzet / Gulmez, Ahmet / Cakar, Burcu / Gursoy, Pinar / Yildirim, Mahmut Emre / Ayhan, Murat /
    Karadurmus, Nuri / Aykan, Musa Baris / Cevik, Gökcen Tugba / Sakalar, Teoman / Hacibekiroglu, Ilhan / Gülbagci, Burcu Belen / Dincer, Murat / Garbioglu, Duygu Bayir / Kemal, Yasemin / Nayir, Erdinc / Taskaynatan, Halil / Yilmaz, Mesut / Avci, Okan / Sari, Murat / Coban, Ezgi / Atci, Muhammed Mustafa / Esen, Selin Aktürk / Telli, Tugba Akin / Karatas, Fatih / Inal, Ali / Demir, Hacer / Kalkan, Nurhan Onal / Yilmaz, Cengiz / Tasli, Funda / Alacacioglu, Ahmet

    Anti-cancer drugs

    2022  Volume 33, Issue 7, Page(s) 663–670

    Abstract: In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology Group ...

    Abstract In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology Group (TOG) with data collected from 32 centers. Our study was multicentric, and a total of 364 patients were included. The median age of the patients was 49 years (18-85 years). Two hundred fifteen (60%) of the cases were hormone receptor/HER2+ positive(ER+ or PR+, or both), and 149 (40%) of them were HER2-rich (ER and PR negative). The number of complete responses was 124 (54%) in the docetaxel+trastuzumab+pertuzumab arm and 102 (45%) in the paclitaxel+trastuzumab+pertuzumab arm, and there was no difference between the groups in terms of complete response. In 226 (62%) patients with complete response, a significant correlation was found with DCIS, tumor focality, removed lymph node, and ER status P < 0.05. Anemia, nausea, vomiting, myalgia, alopecia, and mucosal inflammation were significantly higher in the docetaxel arm, P < 0.05. In our study, no statistical difference was found between the before-after echocardiography values. DCIS positivity in biopsy before neoadjuvant chemotherapy, tumor focality; the number of lymph nodes removed and ER status were found to be associated with pCR. In conclusion, we think that studies evaluating pCR-related clinicopathological variables and radiological imaging features will play a critical role in the development of nonsurgical treatment approaches.
    MeSH term(s) Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/pathology ; Carcinoma, Intraductal, Noninfiltrating/drug therapy ; Carcinoma, Intraductal, Noninfiltrating/etiology ; Docetaxel/therapeutic use ; Female ; Humans ; Middle Aged ; Neoadjuvant Therapy/methods ; Receptor, ErbB-2/metabolism ; Trastuzumab/adverse effects
    Chemical Substances Antibodies, Monoclonal, Humanized ; Biomarkers, Tumor ; Docetaxel (15H5577CQD) ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1) ; pertuzumab (K16AIQ8CTM) ; Trastuzumab (P188ANX8CK)
    Language English
    Publishing date 2022-06-20
    Publishing country England
    Document type Journal Article
    ZDB-ID 1065301-6
    ISSN 1473-5741 ; 0959-4973
    ISSN (online) 1473-5741
    ISSN 0959-4973
    DOI 10.1097/CAD.0000000000001310
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3125: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.

    Karacin, Cengiz / Oksuzoglu, Berna / Demirci, Ayşe / Keskinkılıç, Merve / Baytemür, Naziyet Köse / Yılmaz, Funda / Selvi, Oğuzhan / Erdem, Dilek / Avşar, Esin / Paksoy, Nail / Demir, Necla / Göksu, Sema Sezgin / Türker, Sema / Bayram, Ertuğrul / Çelebi, Abdüssamet / Yılmaz, Hatice / Kuzu, Ömer Faruk / Kahraman, Seda / Gökmen, İvo /
    Sakin, Abdullah / Alkan, Ali / Nayır, Erdinç / Uğraklı, Muzaffer / Acar, Ömer / Ertürk, İsmail / Demir, Hacer / Aslan, Ferit / Sönmez, Özlem / Korkmaz, Taner / Celayir, Özde Melisa / Karadağ, İbrahim / Kayıkçıoğlu, Erkan / Şakalar, Teoman / Öktem, İlker Nihat / Eren, Tülay / Erul, Enes / Mocan, Eda Eylemer / Kalkan, Ziya / Yıldırım, Nilgün / Ergün, Yakup / Akagündüz, Baran / Karakaya, Serdar / Kut, Engin / Teker, Fatih / Demirel, Burçin Çakan / Karaboyun, Kubilay / Almuradova, Elvina / Ünal, Olçun Ümit / Oyman, Abdilkerim / Işık, Deniz / Okutur, Kerem / Öztosun, Buğra / Gülbağcı, Burcu Belen / Kalender, Mehmet Emin / Şahin, Elif / Seyyar, Mustafa / Özdemir, Özlem / Selçukbiricik, Fatih / Kanıtez, Metin / Dede, İsa / Gümüş, Mahmut / Gökmen, Erhan / Yaren, Arzu / Menekşe, Serkan / Ebinç, Senar / Aksoy, Sercan / İmamoğlu, Gökşen İnanç / Altınbaş, Mustafa / Çetin, Bülent / Uluç, Başak Oyan / Er, Özlem / Karadurmuş, Nuri / Erdoğan, Atike Pınar / Artaç, Mehmet / Tanrıverdi, Özgür / Çiçin, İrfan / Şendur, Mehmet Ali Nahit / Oktay, Esin / Bayoğlu, İbrahim Vedat / Paydaş, Semra / Aydıner, Adnan / Salim, Derya Kıvrak / Geredeli, Çağlayan / Yavuzşen, Tuğba / Doğan, Mutlu / Hacıbekiroğlu, İlhan

    BMC cancer

    2023  Volume 23, Issue 1, Page(s) 136

    Abstract: Background: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists ...

    Abstract Background: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based).
    Methods: A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ≥ 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy.
    Results: The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0-14.0) months in the ET arm of group A, and 5.3 (3.9-6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8-7.7) months in the ET arm of group B, and 5.7 (4.6-6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5-8.0) months in the ET arm of group C and 4.0 (3.5-4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months.
    Conclusion: Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET.
    MeSH term(s) Humans ; Female ; Breast Neoplasms ; Everolimus ; Receptor, ErbB-2/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Fulvestrant/therapeutic use ; Disease Progression ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
    Chemical Substances Everolimus (9HW64Q8G6G) ; Receptor, ErbB-2 (EC 2.7.10.1) ; Protein Kinase Inhibitors ; Fulvestrant (22X328QOC4)
    Language English
    Publishing date 2023-02-10
    Publishing country England
    Document type Journal Article
    ZDB-ID 2041352-X
    ISSN 1471-2407 ; 1471-2407
    ISSN (online) 1471-2407
    ISSN 1471-2407
    DOI 10.1186/s12885-023-10609-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.

    Karacin, Cengiz / Oksuzoglu, Berna / Demirci, Ayşe / Keskinkılıç, Merve / Baytemür, Naziyet Köse / Yılmaz, Funda / Selvi, Oğuzhan / Erdem, Dilek / Avşar, Esin / Paksoy, Nail / Demir, Necla / Göksu, Sema Sezgin / Türker, Sema / Bayram, Ertuğrul / Çelebi, Abdüssamet / Yılmaz, Hatice / Kuzu, Ömer Faruk / Kahraman, Seda / Gökmen, İvo /
    Sakin, Abdullah / Alkan, Ali / Nayır, Erdinç / Uğraklı, Muzafer / Acar, Ömer / Ertürk, İsmail / Demir, Hacer / Aslan, Ferit / Sönmez, Özlem / Korkmaz, Taner / Celayir, Özde Melisa / Karadağ, İbrahim / Kayıkçıoğlu, Erkan / Şakalar, Teoman / Öktem, İlker Nihat / Eren, Tülay / Erul, Enes / Mocan, Eda Eylemer / Kalkan, Ziya / Yıldırım, Nilgün / Ergün, Yakup / Akagündüz, Baran / Karakaya, Serdar / Kut, Engin / Teker, Fatih / Demirel, Burçin Çakan / Karaboyun, Kubilay / Almuradova, Elvina / Ünal, Olçun Ümit / Oyman, Abdilkerim / Işık, Deniz / Okutur, Kerem / Öztosun, Buğra / Gülbağcı, Burcu Belen / Kalender, Mehmet Emin / Şahin, Elif / Seyyar, Mustafa / Özdemir, Özlem / Selçukbiricik, Fatih / Kanıtez, Metin / Dede, İsa / Gümüş, Mahmut / Gökmen, Erhan / Yaren, Arzu / Menekşe, Serkan / Ebinç, Senar / Aksoy, Sercan / İmamoğlu, Gökşen İnanç / Altınbaş, Mustafa / Çetin, Bülent / Uluç, Başak Oyan / Er, Özlem / Karadurmuş, Nuri / Erdoğan, Atike Pınar / Artaç, Mehmet / Tanrıverdi, Özgür / Çiçin, İrfan / Şendur, Mehmet Ali Nahit / Oktay, Esin / Bayoğlu, İbrahim Vedat / Paydaş, Semra / Aydıner, Adnan / Salim, Derya Kıvrak / Geredeli, Çağlayan / Yavuzşen, Tuğba / Doğan, Mutlu / Hacıbekiroğlu, İlhan

    BMC cancer

    2023  Volume 23, Issue 1, Page(s) 192

    Language English
    Publishing date 2023-02-27
    Publishing country England
    Document type Published Erratum
    ZDB-ID 2041352-X
    ISSN 1471-2407 ; 1471-2407
    ISSN (online) 1471-2407
    ISSN 1471-2407
    DOI 10.1186/s12885-023-10662-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Evaluation of Nutritional Practices in the Critical Care patient (The ENPIC study): Does nutrition really affect ICU mortality?

    Servia-Goixart, Lluís / Lopez-Delgado, Juan C. / Grau-Carmona, Teodoro / Trujillano-Cabello, Javier / Bordeje-Laguna, M Luisa / Mor-Marco, Esther / Portugal-Rodriguez, Esther / Lorencio-Cardenas, Carol / Montejo-Gonzalez, Juan C. / Vera-Artazcoz, Paula / Macaya-Redin, Laura / Martinez-Carmona, Juan Francisco / Iglesias-Rodriguez, Rayden / Monge-Donaire, Diana / Flordelis-Lasierra, José L. / Llorente-Ruiz, Beatriz / Menor-Fernández, Eva M. / Martínez de Lagrán, Itziar / Yebenes-Reyes, Juan C. /
    Escobar-Ortiz, Joan / Montserrat-Ortiz, Neus / Zapata-Rojas, Amalia / Bautista-Redondo, Iris / Cruz-Ramos, Ana / Diaz-Castellanos, Laura / Morales-Cifuentes, Miriam / Bono, Montserrat Plaza- / Montejo-Gonzalez, Juan Carlos / Temprano-Vazquez, Susana / Arjona-Diaz, Veronica / Garcia-Fuentes, Carlos / Mudarra-Reche, Carolina / Orejana-Martin, Maria / Lopez-Delgado, Juan Carlos / Lores-Obradors, Africa / Anguela-Calvet, Laura / Muñoz-Del Río, Gloria / Revelo-Esquibel, Pamela Alejandra / Alanez-Saavedra, Henry / Serra-Paya, Pau / Luna-Solis, Stephani Maria / Salinas-Canovas, Alvaro / De Frutos-Seminario, Fernando / Rodriguez-Queralto, Oriol / Gonzalez-Iglesias, Carlos / Zamora-Elson, Monica / Fuente-O'Connor, Eugenia de la / Arbeloa, Carlos Seron- / Bueno-Vidales, Nestor / Martin-Luengo, Ana / Sanchez-Miralles, Angel / Marmol-Peis, Enrique / Ruiz-Miralles, Miriam / Gonzalez-Sanz, Maria / Server-Martinez, Arantzazu / Vila-Garcia, Belen / Flecha-Viguera, Raquel / Aldunate-Calvo, Sara / Flordelis-Lasierra, Jose Luis / Rio, Irene Jimenez-del / Mampaso-Recio, Jose Ramon / Rodriguez-Roldan, Jose Manuel / Gastaldo-Simeon, Rosa / Gimenez-Castellanos, Josefina / Fernandez-Ortega, Juan Francisco / Martinez-Carmona, Juan F. / Lopez-Luque, Esther / Ortega-Ordiales, Ane / Crespo-Gomez, Monica / Ramirez-Montero, Victor / Lopez-García, Esther / Navarro-Lacalle, Arturo / Martinez-Garcia, Pilar / Dominguez-Fernandez, Maria Inmaculada / Izura-Gomez, Marta / Hernandez-Duran, Susana / Bordeje-Laguna, Ma Luisa / Rovira-Valles, Yaiza / Philibert, Viridiana / Alcazar-Espin, Maravillas de las Nieves / Higon-Cañigral, Aurea / Calvo-Herranz, Enrique / Manzano-Moratinos, Diego / Andaluz-Ojeda, David / Parra-Morais, Laura / Citores-Gonzalez, Rafael / Garcia-Gonzalez, Maria Teresa / Sanchez-Giron, Gloria Renedo / Navas-Moya, Elisabeth / Ferrer-Pereto, Carles / Lluch-Candal, Cristina / Ruiz-Izquierdo, Jessica / Castor-Bekari, Silvia / Leon-Cinto, Cristina / Martinez de Lagran, Itziar / Yebenes-Reyes, Juan Carlos / Nieto-Martino, Beatriz / Vaquerizo-Alonso, Clara / Almanza-Lopez, Susana / Perez-Quesada, Sonia / Anton-Pascual, Jose Luis / Marin-Corral, Judith / Sistachs-Baquedano, Maite / Hacer-Puig, Maria / Picornell-Noguera, Marina / Mateu-Campos, Lidon / Martinez-Valero, Clara / Ortiz-Suñer, Andrea / Martinez-Diaz, María Cristina / Muñoz De La Peña, Maria Trascasa- / Rodriguez-Serrano, Diego Anibal / Fernandez-Salvatierra, Leticia / Barcelo-Castello, Mireia / Millan-Taratiel, Paula / Tejada-Artigas, Antonio / Martinez-Arroyo, Ines / Araujo-Aguilar, Pilar / Fuster-Cabre, Maria / Andres-Gines, Laura / Soldado-Olmo, Sonia / Menor-Fernandez, Eva Mª / Lage-Cendon, Lucas / Touceda-Bravo, Alberto / Sanchez-Ales, Laura / Almorin-Gonzalvez, Laura / Gero-Escapa, Maria / Martinez-Barrio, Esther / Ossa-Echeverri, Sergio

    Clinical nutrition ESPEN. 2022 Feb., v. 47

    2022  

    Abstract: The importance of artificial nutritional therapy is underrecognized, typically being considered an adjunctive rather than a primary therapy. We aimed to evaluate the influence of nutritional therapy on mortality in critically ill patients.This ... ...

    Institution ENPIC Study Investigators
    Abstract The importance of artificial nutritional therapy is underrecognized, typically being considered an adjunctive rather than a primary therapy. We aimed to evaluate the influence of nutritional therapy on mortality in critically ill patients.This multicenter prospective observational study included adult patients needing artificial nutritional therapy for >48 h if they stayed in one of 38 participating intensive care units for ≥72 h between April and July 2018. Demographic data, comorbidities, diagnoses, nutritional status and therapy (type and details for ≤14 days), and outcomes were registered in a database. Confounders such as disease severity, patient type (e.g., medical, surgical or trauma), and type and duration of nutritional therapy were also included in a multivariate analysis, and hazard ratios (HRs) and 95% confidence intervals (95%CIs) were reported.We included 639 patients among whom 448 (70.1%) and 191 (29.9%) received enteral and parenteral nutrition, respectively. Mortality was 25.6%, with non-survivors having the following characteristics: older age; more comorbidities; higher Sequential Organ Failure Assessment (SOFA) scores (6.6 ± 3.3 vs 8.4 ± 3.7; P < 0.001); greater nutritional risk (Nutrition Risk in the Critically Ill [NUTRIC] score: 3.8 ± 2.1 vs 5.2 ± 1.7; P < 0.001); more vasopressor requirements (70.4% vs 83.5%; P=0.001); and more renal replacement therapy (12.2% vs 23.2%; P=0.001). Multivariate analysis showed that older age (HR: 1.023; 95% CI: 1.008–1.038; P=0.003), higher SOFA score (HR: 1.096; 95% CI: 1.036–1.160; P=0.001), higher NUTRIC score (HR: 1.136; 95% CI: 1.025–1.259; P=0.015), requiring parenteral nutrition after starting enteral nutrition (HR: 2.368; 95% CI: 1.168–4.798; P=0.017), and a higher mean Kcal/Kg/day intake (HR: 1.057; 95% CI: 1.015–1.101; P=0.008) were associated with mortality. By contrast, a higher mean protein intake protected against mortality (HR: 0.507; 95% CI: 0.263–0.977; P=0.042).Old age, higher organ failure scores, and greater nutritional risk appear to be associated with higher mortality. Patients who need parenteral nutrition after starting enteral nutrition may represent a high-risk subgroup for mortality due to illness severity and problems receiving appropriate nutritional therapy. Mean calorie and protein delivery also appeared to influence outcomes.ClinicaTrials.gov NCT: 03634943.
    Keywords adults ; clinical nutrition ; databases ; disease severity ; enteral feeding ; hemodialysis ; mortality ; multivariate analysis ; nutrition risk assessment ; nutritional status ; observational studies ; parenteral feeding ; patients ; protein intake ; risk
    Language English
    Dates of publication 2022-02
    Size p. 325-332.
    Publishing place Elsevier Ltd
    Document type Article
    ISSN 2405-4577
    DOI 10.1016/j.clnesp.2021.11.018
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top